

Special Issue

New Antibiotic Compounds: Discovery and Strategies

Message from the Guest Editors

This Special Issue welcomes all submissions related to antibacterial discovery. Perspectives (opinion letters) and submissions focusing on requirements to improve/accelerate antibacterial screening and hit to lead translation are encouraged. Potential topics include but are not limited to the following:

- Natural or synthetic antibacterial compounds;
- Antibiotic potentiators, efflux pumps inhibitors;
- Antivirulence, antibiofilm, and/or quorum quenchers;
- Microbial genome mining for antibiotic discovery;
- New strategies to enhance high throughput screening (from natural or synthetic libraries);
- Natural products dereplication strategies;
- Antibiotic discovery platforms.

Keywords: antibiotic; antimicrobial; discovery; high-throughput; screen; molecule-based strategies

Guest Editors

Dr. Florie Desriac

CBSA, Bacterial Communication and Antimicrobial Strategies,
University of Caen Normandie, Caen, France

Dr. Yannick Fleury

LBCM, Laboratoire de Biotechnologie et Chimie Marines Université de
Brest, Quimper, France

Deadline for manuscript submissions

closed (31 May 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/109101

Antibiotics

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(General Pharmacology, Toxicology and Pharmaceutics)